Drugs / Claudin18.2 CAR-T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07066995 | Apr 2025 → Dec 2027 expected | pancreatic ductal adenocarcinoma | Essen Biotech | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05620732 | Oct 2022 → Oct 2025 overdue | gastric carcinoma | Shenzhen University General Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Claudin18.2 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05620732 ↗ |
| Modality | Cell therapy | “Claudin18.2 CAR-T cells” NCT05620732 ↗ |
| Route | Intravenous | “Mesothelin and Claudin 18.2 CAR T cells intravenously (IV) over a duration of 10-20 minutes on day 0” NCT07066995 ↗ |